(GNFT) Genfit S.A. - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: PA (France) | Market Cap: 438m EUR | Total Return: 133.1% in 12m
Industry Rotation: -6.3
Avg Turnover: 1.44M
Warnings
High Debt/EBITDA (28.5) with thin interest coverage (-10.0)
High Debt while negative Cash Flow
Interest Coverage Ratio -10.0 is critical
Beneish M-Score -1.37 > -1.5 - likely earnings manipulation
Altman Z'' -11.56 < 1.0 - financial distress zone
Tailwinds
Leader, Tailwind, Pullback 52w
Genfit S.A. is a French late-stage biopharmaceutical firm specializing in therapeutic and diagnostic solutions for metabolic and liver diseases. The company’s primary focus is the development of Elafibranor for primary biliary cholangitis and the NIS4 diagnostic technology for nonalcoholic steatohepatitis (NASH). Its pipeline further extends to treatments for acute-on-chronic liver failure and cholangiocarcinoma through various clinical phases.
The business model relies on a hybrid approach of internal R&D and strategic licensing, exemplified by its partnership with Labcorp for the commercialization of molecular diagnostic tests. In the biotechnology sector, companies often mitigate high R&D costs by securing royalty-bearing agreements with established global laboratories to manage large-scale distribution.
Further evaluation of the companys financial health and pipeline progress can be conducted on ValueRay. Genfit operates within the orphan drug and liver disease markets, where regulatory designations like Fast Track or Breakthrough Therapy can significantly impact the timeline for commercialization and market exclusivity.
- FDA approval and commercial launch of Elafibranor for primary biliary cholangitis
- Milestone payments and royalties from Labcorp diagnostic technology licensing agreements
- Clinical trial results for VS-01 in acute-on-chronic liver failure treatment
- Pipeline expansion and R&D expenditure for early-stage liver disease drug candidates
- Regulatory hurdles for NASH diagnostic tools impacting long-term market penetration strategies
| Net Income: -84.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.07 > 0.02 and ΔFCF/TA 41.33 > 1.0 |
| NWC/Revenue: 52.09% < 20% (prev 261.3%; Δ -209.2% < -1%) |
| CFO/TA -0.06 > 3% & CFO -9.89m > Net Income -84.5m |
| Net Debt (49.6m) to EBITDA (1.74m): 28.47 < 3 |
| Current Ratio: 2.00 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.9m) vs 12m ago 0.32% < -2% |
| Gross Margin: 62.96% > 18% (prev 0.99%; Δ 6.20k% > 0.5%) |
| Asset Turnover: 83.29% > 50% (prev 16.43%; Δ 66.86% > 0%) |
| Interest Coverage Ratio: -9.98 > 6 (EBITDA TTM 1.74m / Interest Expense TTM 5.09m) |
| A: 0.46 (Total Current Assets 144.3m - Total Current Liabilities 72.3m) / Total Assets 157.9m |
| B: -3.01 (Retained Earnings -475.4m / Total Assets 157.9m) |
| C: -0.31 (EBIT TTM -50.8m / Avg Total Assets 165.9m) |
| D: -2.55 (Book Value of Equity -462.4m / Total Liabilities 181.6m) |
| Altman-Z'' Score: -11.56 = D |
| DSRI: 0.25 (Receivables 40.3m/32.7m, Revenue 138.2m/28.6m) |
| GMI: 1.57 (GM 62.96% / 98.95%) |
| AQI: 0.14 (AQ_t 0.04 / AQ_t-1 0.30) |
| SGI: 4.84 (Revenue 138.2m / 28.6m) |
| TATA: -0.47 (NI -84.5m - CFO -9.89m) / TA 157.9m) |
| Beneish M-Score: -1.37 (Cap -4..+1) = D |
Over the past week, the price has changed by +0.94%, over one month by -6.32%, over three months by +7.17% and over the past year by +133.06%.
| Analysts Target Price | - | - |
P/E Forward = 7.5472
P/S = 6.698
P/B = 7.5961
Revenue TTM = 138.2m EUR
EBIT TTM = -50.8m EUR
EBITDA TTM = 1.74m EUR
Long Term Debt = 105.0m EUR (from longTermDebt, last quarter)
Short Term Debt = 42.9m EUR (from shortTermDebt, last quarter)
Debt = 150.7m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 49.6m EUR (from netDebt column, last quarter)
Enterprise Value = 487.9m EUR (438.3m + Debt 150.7m - CCE 101.1m)
Interest Coverage Ratio = -9.98 (Ebit TTM -50.8m / Interest Expense TTM 5.09m)
EV/FCF = -41.64x (Enterprise Value 487.9m / FCF TTM -11.7m)
FCF Yield = -2.40% (FCF TTM -11.7m / Enterprise Value 487.9m)
FCF Margin = -8.48% (FCF TTM -11.7m / Revenue TTM 138.2m)
Net Margin = -61.13% (Net Income TTM -84.5m / Revenue TTM 138.2m)
Gross Margin = 62.96% ((Revenue TTM 138.2m - Cost of Revenue TTM 51.2m) / Revenue TTM)
Gross Margin QoQ = -56.26% (prev none%)
Tobins Q-Ratio = 3.09 (Enterprise Value 487.9m / Total Assets 157.9m)
Interest Expense / Debt = 0.21% (Interest Expense 314k / Debt 150.7m)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -38.1m (EBIT -50.8m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 2.00 (Total Current Assets 144.3m / Total Current Liabilities 72.3m)
Debt / Equity = -6.37 (negative equity) (Debt 150.7m / totalStockholderEquity, last quarter -23.6m)
Debt / EBITDA = 28.47 (Net Debt 49.6m / EBITDA 1.74m)
Debt / FCF = -4.23 (negative FCF - burning cash) (Net Debt 49.6m / FCF TTM -11.7m)
Total Stockholder Equity = 48.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -50.91% (Net Income -84.5m / Total Assets 157.9m)
RoE = -172.9% (Net Income TTM -84.5m / Total Stockholder Equity 48.9m)
RoCE = -33.01% (EBIT -50.8m / Capital Employed (Equity 48.9m + L.T.Debt 105.0m))
RoIC = -32.76% (negative operating profit) (NOPAT -38.1m / Invested Capital 116.3m)
WACC = 6.23% (E(438.3m)/V(589.0m) * Re(8.32%) + D(150.7m)/V(589.0m) * Rd(0.21%) * (1-Tc(0.25)))
Discount Rate = 8.32% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 47.74 | Cagr: 0.17%
[DCF] Fair Price = unknown (Cash Flow -11.7m)
EPS Correlation: -66.83 | EPS CAGR: -86.01% | SUE: N/A | # QB: 0
Revenue Correlation: 57.16 | Revenue CAGR: 1.72k% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=-0.65 | Chg30d=-402.98% | Revisions=-33% | GrowthEPS=-37.9% | GrowthRev=-3.5%
EPS next Year (2027-12-31): EPS=-0.73 | Chg30d=-478.62% | Revisions=-33% | GrowthEPS=-12.6% | GrowthRev=+45.7%
[Analyst] Revisions Ratio: -33%